Related Experiment Video
Updated: Apr 24, 2026
07:36
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
Published on: September 26, 2018
9.7K
Mineralcorticoid antagonists in heart failure
1Cardiovascular Department, Papa Giovanni XXIII Hospital, Piazza OMS 1, Bergamo 24127, Italy; University of Pavia, Piazzale Golgi 1, Pavia 27100, Italy.
Heart Failure Clinics
|September 14, 2014
Summary
Mineralocorticoid receptor antagonists (MRAs) are essential for treating heart failure (HF) with reduced ejection fraction. This review covers their role in HF, aldosterone
Area of Science:
- Cardiology
- Pharmacology
Background:
- Mineralocorticoid receptor antagonists (MRAs) are guideline-directed medical therapy for heart failure (HF) with reduced ejection fraction (HFrEF).
- Aldosterone plays a key role in the pathophysiology of HF.
Purpose of the Study:
- To review the pathophysiological role of aldosterone and MRAs in HFrEF.
- To summarize clinical data supporting MRA use in systolic HF.
- To explore emerging applications and newer agents.
Main Methods:
- Review of pathophysiological mechanisms.
- Summary of pivotal clinical trial data.
- Discussion of current and future therapeutic strategies.
Main Results:
- MRAs are indicated in all patients with symptomatic HFrEF.
- Early MRA initiation is recommended post-myocardial infarction in specific patient groups.
- Evidence supports expanded use beyond traditional indications.
Conclusions:
- MRAs are a cornerstone therapy for HFrEF.
- Further research is exploring novel applications and agents for cardiovascular conditions.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.6K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.6K
01:22Heart Failure Drugs: Diuretics
1.3K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.3K
01:30Heart Failure V: Medical Management
611
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
611
01:22Heart Failure Drugs: β-Blockers
2.4K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.4K
01:26Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.6K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.6K